InVivoSIM anti-human CD27 (Varlilumab Biosimilar)

About InVivoSIM anti-human CD27 (Varlilumab Biosimilar)

This non‑therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Varlilumab, making it ideal for research use. Varlilumab is a human IgG1 monoclonal antibody that specifically targets CD27, a member of the tumor necrosis factor receptor (TNFR) superfamily. CD27 is a co-stimulatory immune receptor that is constitutively expressed on naive and memory T cells, and can also be found on regulatory T cells (Tregs), NK cells, and some B cells. Engagement of CD27 by its ligand, CD70, promotes T cell activation, survival, and effector function, playing a key role in regulating immune responses and maintaining long-term immunity. Varlilumab is an agonist antibody that mimics CD70 binding, delivering potent co-stimulatory signals to T cells while also depleting CD27⁺ regulatory T cells via Fc-mediated effector mechanisms. Varlilumab has shown therapeutic potential in enhancing anti-tumor immunity in cancer models and has been investigated in combination with immune checkpoint inhibitors such as anti-PD-1. This Varlilumab biosimilar is ideal for studying CD27 signaling, T cell costimulation, Treg modulation, and combination immunotherapy mechanisms in both in vitro and in vivo settings.